New liver results for Wegovy 2.4 mg and the investigational efruxifermin are headed to The Liver Meeting this year.
Recap by typeshit. Post by @doepke_michel on X.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Mounjaro and Zepbound still carry Lilly, but neuroscience sales rose 32% in the first half of 2026. Lilly reports third-quarter results on Oct. 29.
That's up from 9% a year ago, and coverage fell to 53% from 57%. 24/7 Wall St. looks at what cash pricing means for Lilly and Novo ahead of earnings.
Loading…